Next Article in Journal
Epidermal Growth Factor Receptor Inhibitor–Induced Hypomagnesemia: A Survey of Practice Patterns among Canadian Gastrointestinal Medical Oncologists
Previous Article in Journal
A Systematic Review of Acupuncture for Chemotherapy-Induced Peripheral Neuropathy
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 26
Issue 2
10.3747/co.26.4501
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Impact of a Novel Prioritization Framework on Clinician-Led Oncology Drug Submissions

by
J. Keech
1,2,
J. Beca
1,2,
A. Eisen
1,3,
E. Kennedy
1,4,
J. Kim
1,5,
C.T. Kouroukis
1,6,
G. Darling
1,5,
S.E. Ferguson
1,5,
A. Finelli
1,5,
T.M. Petrella
1,3,
J.R. Perry
1,3,
K. Chan
1,2,3,* and
S. Gavura
1
1
Cancer Care Ontario, Toronto, ON, Canada
2
Canadian Centre for Applied Research in Cancer Control, Toronto, ON, Canada
3
Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada
4
Mount Sinai Hospital, Toronto, ON, Canada
5
Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
6
Juravinski Cancer Centre, Hamilton Health Sciences, Hamilton, ON, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2019, 26(2), 155-161; https://doi.org/10.3747/co.26.4501
Submission received: 5 January 2019 / Revised: 6 February 2019 / Accepted: 7 March 2019 / Published: 1 April 2019

Abstract

Background: In Canada, requests for public reimbursement of cancer drugs are predominately initiated by pharmaceutical manufacturers. Clinician-led submissions provide a mechanism to initiate the drug funding process when industry does not submit a request for funding consideration. Although such requests are resource-intensive to produce, Cancer Care Ontario (CCO) has the capacity to facilitate clinician-led submissions. In 2014, CCO began developing a cancer drug prioritization framework that allocates resources to systematically address a growing number of clinician-identified funding gaps with clinician-led submissions. Methods: Cancer site–specific drug advisory committees established by CCO consist of health care practitioners whose roles include identifying and prioritizing funding gaps. The committees submit their identified gaps to a cross-cancer-site prioritization exercise in which the requests are ranked based on a set of guiding principles derived from health technology assessment. The requests are then sequentially allocated the resources needed to meet submission requirements. Whether the funding gap is of provincial or pan-Canadian relevance determines where the submission is filed for assessment. Results: Since its inception, the CCO framework has identified 17 funding gaps in 9 cancer sites. In 4 prioritizations, the framework supported 6 submissions. As of June 2018, the framework had contributed to the eventual funding of more than 9 new drug–indication pairs, with more awaiting funding consideration. Conclusions: The CCO prioritization framework has enabled clinicians to effectively and systematically identify, prioritize, and fill funding gaps not addressed by industry. Ultimately, the framework helps to ensure that patients can access evidence-informed and cost-effective therapies. The framework will continue to evolve as it encounters new challenges, including funding requests for rare indications.
Keywords: drug funding; health technology assessment; prioritization; clinician-led funding submissions drug funding; health technology assessment; prioritization; clinician-led funding submissions

Share and Cite

MDPI and ACS Style

Keech, J.; Beca, J.; Eisen, A.; Kennedy, E.; Kim, J.; Kouroukis, C.T.; Darling, G.; Ferguson, S.E.; Finelli, A.; Petrella, T.M.; et al. Impact of a Novel Prioritization Framework on Clinician-Led Oncology Drug Submissions. Curr. Oncol. 2019, 26, 155-161. https://doi.org/10.3747/co.26.4501

AMA Style

Keech J, Beca J, Eisen A, Kennedy E, Kim J, Kouroukis CT, Darling G, Ferguson SE, Finelli A, Petrella TM, et al. Impact of a Novel Prioritization Framework on Clinician-Led Oncology Drug Submissions. Current Oncology. 2019; 26(2):155-161. https://doi.org/10.3747/co.26.4501

Chicago/Turabian Style

Keech, J., J. Beca, A. Eisen, E. Kennedy, J. Kim, C.T. Kouroukis, G. Darling, S.E. Ferguson, A. Finelli, T.M. Petrella, and et al. 2019. "Impact of a Novel Prioritization Framework on Clinician-Led Oncology Drug Submissions" Current Oncology 26, no. 2: 155-161. https://doi.org/10.3747/co.26.4501

APA Style

Keech, J., Beca, J., Eisen, A., Kennedy, E., Kim, J., Kouroukis, C. T., Darling, G., Ferguson, S. E., Finelli, A., Petrella, T. M., Perry, J. R., Chan, K., & Gavura, S. (2019). Impact of a Novel Prioritization Framework on Clinician-Led Oncology Drug Submissions. Current Oncology, 26(2), 155-161. https://doi.org/10.3747/co.26.4501

Article Metrics

Back to TopTop